ChemoCentryx, Inc. Announces Phase I Data With CCX507, Company's New Generation Orally Administered CCR9 Inhibitor

Published: May 21, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MOUNTAIN VIEW, Calif. and ORLANDO, Fla., May 21, 2013 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced data showing that CCX507, a next generation orally available inhibitor of the chemokine receptor known as CCR9, exhibited excellent pharmacokinetics and was well tolerated in a Phase I trial in healthy subjects. Preclinical data were also presented, showing that CCX507 markedly inhibited the recruitment of T cells to the intestine and significantly reduced colitis and colitis-associated wasting in inflammatory bowel disease models. The data, which were presented in a poster presentation at the Digestive Disease Week 2013 conference in Orlando, further strengthen the rationale for the use of a CCR9 antagonist in inflammatory bowel disease (IBD).

Help employers find you! Check out all the jobs and post your resume.

Back to news